These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Suppressor-type TERT mutations associated with recurrence in ovarian clear cell carcinoma.
    Author: Kobayashi T, Nishikimi K, Mitsuhashi A, Piao H, Matsuoka A, Otsuka S, Tate S, Shozu M, Usui H.
    Journal: Genes Chromosomes Cancer; 2023 Aug; 62(8):471-476. PubMed ID: 36710084.
    Abstract:
    Several cancers harbor "enhancer-type" mutations of the telomerase reverse transcriptase (TERT) promoter for immortalization. Here, we report that 8.6% (8/93) of ovarian clear cell carcinomas (OCCCs) possess the "suppressor-type" TERT promoter mutation. The recurrence rate of OCCCs with "suppressor-type" TERT promoter mutations was 62.5% (5/8) and was significantly higher than that of the "unaffected-type" with no mutation (20.8%, 15/72) or "enhancer-type" TERT promoter mutations (7.7%, 1/13). Our findings show that the acquired suppression of TERT is closely associated with OCCC development and recurrence, indicating the need for further research on telomerase suppression in cancers.
    [Abstract] [Full Text] [Related] [New Search]